X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs DR. REDDYS LAB - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA DR. REDDYS LAB TORRENT PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 25.1 27.2 92.2% View Chart
P/BV x 6.1 2.8 219.2% View Chart
Dividend Yield % 3.3 1.0 321.8%  

Financials

 TORRENT PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-16
DR. REDDYS LAB
Mar-16
TORRENT PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,7204,383 39.2%   
Low Rs1,1342,750 41.2%   
Sales per share (Unadj.) Rs394.5920.1 42.9%  
Earnings per share (Unadj.) Rs101.8126.1 80.7%  
Cash flow per share (Unadj.) Rs116.3183.0 63.6%  
Dividends per share (Unadj.) Rs40.0020.00 200.0%  
Dividend yield (eoy) %2.80.6 499.9%  
Book value per share (Unadj.) Rs200.3685.8 29.2%  
Shares outstanding (eoy) m169.22170.61 99.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.63.9 93.3%   
Avg P/E ratio x14.028.3 49.6%  
P/CF ratio (eoy) x12.319.5 62.9%  
Price / Book Value ratio x7.15.2 137.0%  
Dividend payout %39.315.9 247.8%   
Avg Mkt Cap Rs m241,435608,481 39.7%   
No. of employees `00010.921.7 50.3%   
Total wages/salary Rs m8,55931,874 26.9%   
Avg. sales/employee Rs Th6,129.67,244.4 84.6%   
Avg. wages/employee Rs Th785.81,470.9 53.4%   
Avg. net profit/employee Rs Th1,581.3992.8 159.3%   
INCOME DATA
Net Sales Rs m66,764156,978 42.5%  
Other income Rs m2,1562,693 80.1%   
Total revenues Rs m68,920159,671 43.2%   
Gross profit Rs m27,20434,587 78.7%  
Depreciation Rs m2,4619,705 25.4%   
Interest Rs m1,859824 225.6%   
Profit before tax Rs m25,04126,751 93.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1,4030-   
Tax Rs m6,4145,237 122.5%   
Profit after tax Rs m17,22421,514 80.1%  
Gross profit margin %40.722.0 184.9%  
Effective tax rate %25.619.6 130.8%   
Net profit margin %25.813.7 188.2%  
BALANCE SHEET DATA
Current assets Rs m46,622118,201 39.4%   
Current liabilities Rs m32,84368,368 48.0%   
Net working cap to sales %20.631.7 65.0%  
Current ratio x1.41.7 82.1%  
Inventory Days Days7460 123.8%  
Debtors Days Days7997 81.5%  
Net fixed assets Rs m39,02972,265 54.0%   
Share capital Rs m846853 99.2%   
"Free" reserves Rs m31,400111,548 28.1%   
Net worth Rs m33,890117,009 29.0%   
Long term debt Rs m18,63710,690 174.3%   
Total assets Rs m90,136200,104 45.0%  
Interest coverage x14.533.5 43.2%   
Debt to equity ratio x0.50.1 601.9%  
Sales to assets ratio x0.70.8 94.4%   
Return on assets %21.211.2 189.6%  
Return on equity %50.818.4 276.4%  
Return on capital %48.521.6 224.8%  
Exports to sales %43.346.3 93.7%   
Imports to sales %6.99.0 76.7%   
Exports (fob) Rs m28,93472,618 39.8%   
Imports (cif) Rs m4,58414,050 32.6%   
Fx inflow Rs m29,18575,405 38.7%   
Fx outflow Rs m6,02127,115 22.2%   
Net fx Rs m23,16548,290 48.0%   
CASH FLOW
From Operations Rs m27,13240,476 67.0%  
From Investments Rs m-7,014-19,421 36.1%  
From Financial Activity Rs m-14,352-17,009 84.4%  
Net Cashflow Rs m5,7674,046 142.5%  

Share Holding

Indian Promoters % 71.5 25.5 280.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 5.4 130.0%  
FIIs % 12.6 35.3 35.7%  
ADR/GDR % 0.0 18.5 -  
Free float % 8.8 15.3 57.5%  
Shareholders   26,511 75,885 34.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   MERCK LTD  IPCA LABS  NATCO PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 22, 2017 03:36 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - ALEMBIC PHARMA COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS